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ABSTRACT
Phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin 
(mTOR) pathway activation contributes to mantle cell lymphoma (MCL) pathogenesis 
and drug resistance. Antitumor activity has been observed with mTOR inhibitors. 
However, they have shown limited clinical efficacy in relation to drug activation of 
feedback loops. Selective PI3K inhibition or dual PI3K/mTOR catalytic inhibition are 
different therapeutic approaches developed to achieve effective pathway blockage. 
Here, we have performed a comparative analysis of the mTOR inhibitor everolimus, 
the pan-PI3K inhibitor NVP-BKM120 and the dual PI3K/mTOR inhibitor NVP-BEZ235 
in primary MCL cells. We found NVP-BEZ235 to be more powerful than everolimus or 
NVP-BKM120 in PI3K/Akt/mTOR signaling inhibition, indicating that targeting the 
PI3K/Akt/mTOR pathway at multiple levels is likely to be a more effective strategy 
for the treatment of MCL than single inhibition of these kinases.  Among the three 
drugs, NVP-BEZ235 induced the highest change in gene expression profile. Functional 
validation demonstrated that NVP-BEZ235 inhibited angiogenesis, migration and 
tumor invasiveness in MCL cells. NVP-BEZ235 was the only drug able to block IL4 
and IL6/STAT3 signaling which compromise the therapeutic effect of chemotherapy in 
MCL. Our findings support the use of the dual PI3K/mTOR inhibitor NVP-BEZ235 as a 
promising approach to interfere with the microenvironment-related processes in MCL.
INTRODUCTION
Mantle cell lymphoma (MCL) is an aggressive 
B-lymphoid neoplasm with poor response to conventional 
chemotherapy and short survival. It is genetically 
characterized by the chromosomal translocation t(11;14)
(q13;q32), which dysregulates cyclin D1 expression. 
Although cyclin D1 up-regulation is detected in nearly 
all MCL, it is not sufficient for the development of the 
disease. Additional chromosome alterations that target 
genes involved in molecular pathways, such as cell cycle, 
DNA damage response and cell survival, are frequently 
found in MCL.[1]
Constitutive activation of phosphatidylinositol 
3-kinase (PI3K), Akt and mammalian target of rapamycin 
(mTOR) is known to confer drug resistance to many 
types of cancer, including MCL. This pathway integrates 
signals from extracellular stimuli to regulate fundamental 
cellular processes, including mRNA translation, cell 
cycle progression and cell survival.[2] MCL tumors 
frequently express the inactive phosphorylated form of 
PTEN, a negative PI3K regulator, thereby contributing 
to constitutive PI3K signaling.[3] In addition, gene 
amplification of PIK3CA (PI3K p110 catalytic subunit 
alpha) has also been described in MCL.[4]
Selective targeting of PI3K has demonstrated the 
potential to inhibit this pathway. However, the first p110δ 
isoform-selective PI3K inhibitor, idelalisib (GS-1101), 
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with notable results in indolent non-Hodgkin lymphoma[5] 
and chronic lymphocytic leukemia,[6] showed modest 
responses in patients with MCL.[7] Moreover, it has been 
postulated that the increased expression of PI3K p110α 
isoform in MCL particularly at relapse might play a role 
in MCL progression,[8] supporting the use of pan-PI3K 
inhibitors. Currently, multiple PI3K inhibitors are under 
clinical investigation.[9] Among them, NVP-BKM120 
has shown efficacy both in vitro[10-13] and in vivo[14] in 
several malignancies. 
Allosteric mTOR inhibitors, which include 
rapamycin (sirolimus) and its analogues (temsirolimus, 
everolimus and ridaforolimus), mainly target mTORC1 
and also show single agent activity in a range of B-cell 
malignancies.[15] Temsirolimus was approved by 
the European Medicines Agency for the treatment of 
relapsed and refractory MCL, while ridaforolimus and 
everolimus have been entered in several clinical trials.
[16] However, mTORC1-specificity of rapamycin 
analogues may limit its efficacy due to feedback 
activation of upstream PI3K signaling, leading to Akt 
hyperactivation.[17] In this sense, we previously reported 
that activity of the oral mTOR inhibitor everolimus, is 
limited by Akt rephosphorylation and that a selective 
Akt inhibitor overcomes this compensatory reactivation.
[18] In this context, dual PI3K/mTOR inhibitors have 
been synthesized, which, unlike rapamycin and its 
analogues, are ATP competitive inhibitors and target 
the catalytic site of both kinases.[9] These dual PI3K/
mTOR inhibitors have increased antitumor effects due 
to their ability to suppress the prosurvival regulatory 
feedback.[19] NVP-BEZ235 is an orally bioavailable 
imidazoquinoline derivative that inhibits the kinase 
activity of PI3K, mTORC1 and mTORC2.[20] It has 
shown pre-clinical activity against a range of lymphoid 
malignancies[13;19;21-23] and is currently undergoing 
phase I evaluation in acute leukemia (NCT01756118). 
NVP-BEZ235 also exhibited antiproliferative effect 
in MCL cell lines by downregulating Mcl-1[24] and 
synergisms with conventional agents.[25;26] 
In this study, we compared the therapeutic 
potential of the novel dual PI3K/mTOR inhibitor NVP-
BEZ235 to NVP-BKM120 (pan-class I PI3K inhibitor) 
and everolimus (mTORC1 inhibitor) in primary MCL 
samples. Our study supports the view that the concurrent 
suppression of PI3K and mTORC2, in addition to 
mTORC1, is likely to be a more effective strategy for the 
treatment of MCL than single inhibition of these kinases. 
RESULTS
Superior inhibitory activity of NVP-BEZ235 
towards PI3K/Akt/mTOR signaling compared to 
everolimus and NVP-BKM120 in primary MCL 
cells
Cells from 11 primary MCL cases were exposed 
to everolimus (5 µM), NVP-BEZ235 (1 µM) or NVP-
BKM120 (1 µM) for 48 hours and cytotoxicity was 
measured by Annexin V labeling (Table 1). Drug optimal 
doses were selected based on previous studies.[10;18;24] 
These doses showed a low cytotoxic effect in healthy B 
and T lymphocytes (data not shown). Figure 1A the three 
compounds induced significant cytotoxicity compared 
to control (**, P < 0.01; ***, P < 0.001). Among them, 
NVP-BEZ235 induced a high cytotoxic effect with a mean 
response of 40.80 ± 21.30 % which was significantly 
higher than that observed with everolimus (mean response 
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of 22.74 ± 17.63 %; **, P < 0.01). The antitumor effect 
of the pan-PI3K inhibitor NVP-BKM120 reached 31.93 ± 
17.31 %. The sensitivity to these drugs was not related to 
genomic alterations of PI3K/Akt/mTOR (PTEN deletion, 
PIK3CA and AKT1 amplifications) or TP53 alterations 
(Table 1).
We then studied the ability of these drugs to 
overcome stroma-mediated resistance. As expected, 
coculture of primary MCL cells with the stromal cell line 
HS-5 protected MCL cells from spontaneous apoptosis 
after 48 hours of HS-5 coculture (**, P < 0.01; data not 
shown). Of note, the three compounds were able to induce 
apoptosis with the same efficiency despite the presence of 
stromal cells, although only NVP-BEZ235 enhanced MCL 
cell killing in HS-5 coculture (Figure 1B; *, P < 0.05). 
We further evaluated the effect of these compounds 
in the PI3K-mediated signaling. As expected, everolimus 
blocked the activation of the mTOR downstream target 
RPS6 but barely modified phospho-Akt levels, consistent 
with the Akt rephosphorylation after exposure to 
everolimus.[17;18] We also observed that NVP-BKM120 
downregulated the phosphorylation levels of Akt and the 
mTOR targets, RPS6 and EIF4E, while the dual inhibitor 
NVP-BEZ235 demonstrated the greater inhibitory activity 
toward PI3K/Akt/mTOR signaling pathway, with a 
complete reduction of the phosphorylation levels of Akt, 
4EBP1, RPS6 and EIF4E (Figure 1C). 
Thus, in MCL primary cells, dual PI3K/mTOR 
inhibition is the best strategy to efficiently block PI3K-
mediated signaling and to induce major apoptosis, even in 
Figure 1: Cytotoxic effect of everolimus, NVP-BEZ235 and NVP-BKM120 and PI3K/Akt/mTOR signaling inhibition 
in primary MCL cells. A, Primary MCL cells were treated with 5 µM everolimus, 1 µM NVP-BEZ235 or 1 µM NVP-BKM120 for 
48 hours and cytotoxicity was measured by Annexin V labeling. Mean ± SEM of all the samples analyzed (n=11). B, Primary MCL cells 
(n=9) were cocultured with or without HS-5 and incubated with the corresponding drugs as above. Cell viability was assessed by Annexin V 
labeling at 48 hours and calculated relative to the respective untreated control, with or without stroma. Mean ± SEM of the cases analyzed. 
C, MCL cells were exposed for 8 hours to the corresponding drugs as previously. Analysis of phosphorylated and total levels of Akt, RPS6, 
4EBP1 and EIF4E were determined by Western blot. Ratio between phosphorylated and total protein levels was calculated and relative 
protein quantification in treated versus control extracts was conducted with Image Gauge software (Fujifilm). α-tubulin was probed as a 
loading control. Two representative cases are shown (MCL nº.1 and nº.7). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
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the presence of stroma.
NVP-BEZ235 modulates genes related to 
inflammation, cytokine signaling, angiogenesis 
and tumor invasiveness
We next analyzed the impact of these PI3K/Akt/
mTOR inhibitors on gene expression profile (GEP) of 
two representative MCL cases (MCL nº.1 and nº.2, Table 
1) treated for 8 hours with the corresponding drugs. We 
selected the common genes between the two MCL cases 
that were differentially expressed from each treatment 
compared to the control, with an absolute fold change 
above 1.5. Everolimus treatment induced the lowest 
number of gene modulations (118 genes upregulated 
and 68 downregulated), whereas after NVP-BKM120 
treatment 254 genes were upregulated and 290 genes were 
downregulated. Interestingly, NVP-BEZ235 modulated 
the highest number of genes, being 319 genes upregulated 
and 399 downregulated (Figure 2A). Unsupervised 
hierarchical clustering in each case showed that control 
and everolimus-treated samples clustered together, 
consistent with the low number of genes modified by the 
drug. NVP-BKM120-treated samples clustered with the 
previous control-everolimus group. Importantly, NVP-
BEZ235-treated samples showed the most different 
gene expression pattern, as indicated by the independent 
branch of the dendogram (Supplementary Figure A.1). We 
then selected the genes specifically modulated by NVP-
BEZ235 that were not modified by the other inhibitors. 
Figure 2B shows the heatmap of these 619 genes (281 
genes upregulated and 338 genes downregulated) in a 
representative primary MCL case. 
As NVP-BEZ235 came out to be the compound 
that induces more dramatic changes in GEP, we next 
explored the biological networks involved in NVP-
BEZ235 treatment in MCL cells. As shown in Figure 
2C, using gene set enrichment analysis (GSEA) with 
a false discovery rate (FDR) < 0.05 and a normalized 
enrichment score (NES) < -1.7, we identified several 
gene sets negatively enriched in NVP-BEZ235-treated 
cells that were related to respiratory electron transport, 
glucose metabolism, B-cell receptor signaling, cell cycle 
and proliferation, all of them pathways well-known to be 
affected by PI3K/Akt/mTOR inhibitors.[2] In addition, 
we also identified other pathways negatively enriched in 
NVP-BEZ235-treated cells involved in hypoxia response, 
angiogenesis, cell invasion, cytokines and inflammation, 
such as NF-κB pathway, TOLL pathway, IL4 and IL6 
signaling, and STAT3 pathway. Complete information of 
the gene signatures is shown in Supplementary Table A.2.
Altogether, these findings suggest that improved 
antitumor activity of NVP-BEZ235 in MCL is mostly 
Figure 2: Gene expression profile analysis of primary MCL cells treated with everolimus, NVP-BEZ235 or NVP-
BKM120. A, Graph depicting the number of differentially expressed genes from each treatment compared to the control of the two MCL 
cases, with an absolute fold change > 1.5. B, Heatmap illustrating the 619 exclusively expressed genes modulated by NVP-BEZ235 clustered 
according to unsupervised hierarchical clustering analysis. Samples with similar patterns of expression of the genes studied cluster together, 
as indicated by the dendogram. Red indicates increased expression and blue decreased expression relative to the median expression level 
according to the color scale shown. A representative case is shown (MCL nº.2). C, Gene signatures specifically downregulated by NVP-
BEZ235 were obtained with GSEA. Bars represent NES (NES < -1.7). FDR < 0.05 was considered significant.
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associated with its capacity to modulate a high number 
of genes related to angiogenic and invasive processes, 
inflammation and cytokine signaling. 
NVP-BEZ235 blocks IL4 and IL6 signaling in 
MCL cells
In order to validate the relevance of the GSEA gene 
categories related to inflammation and cytokine signaling, 
we selected a subset of the top leading edge genes for 
further analysis in 10 primary MCL cells exposed to the 
different drugs (Supplementary Table A.1). Several genes 
related to the IL4, IL6 and STAT3 signatures, HCK (**, P 
< 0.01), IL6 (*, P < 0.05), IRF1 (*, P < 0.05) and SP110 
(**, P < 0.01) were validated as being downregulated only 
by NVP-BEZ235 treatment. STAT1 was downregulated 
by both everolimus (*, P < 0.05) and NVP-BEZ235 
(**, P < 0.01), although NVP-BEZ235 effect was more 
pronounced. Statistical significance was also achieved 
with TLR4 (**, P < 0.01), from the TOLL pathway 
signature (Figure 3A).
To further study the effect of NVP-BEZ235 in 
interleukin signaling, primary MCL cells were exposed 
to the corresponding drugs in the presence or absence of 
IL4 or IL6 (Figure 3B). We observed that IL4 protected 
MCL cells from spontaneous apoptosis (*, P < 0.05; data 
not shown). Interestingly, while the cytotoxic effect of 
everolimus and NVP-BKM120 was almost completely 
reverted by IL4 (**, P < 0.01 for everolimus; *, P < 
0.05 for NVP-BKM120), no alteration of NVP-BEZ235 
citotoxicity was observed in the presence of IL4. It is 
known that the activating phosphorylation of STAT 
proteins can be triggered by cytokines such as IL4 and 
IL6.[27] As shown in Figure 3C, incubation of primary 
MCL cells with IL4 resulted in the phosphorylation of 
downstream STAT6 and, in a minor degree, of STAT3. 
Consistent with GEP data, NVP-BEZ235 was the only 
drug able to block STAT6 and STAT3 phosphorylation 
after IL4 stimulation, indicating that this compound is 
interfering IL4 signaling in primary MCL cells. In the case 
of IL6 stimulation, despite no differences in viability were 
observed after treatment with the corresponding drugs 
(Figure 3B), only NVP-BEZ235 was able to decrease the 
phosphorylation levels of STAT3 induced by IL6 (Figure 
3C). 
These data demonstrate that only the dual inhibitor 
NVP-BEZ235 is able to hamper IL4 and IL6 signaling in 
MCL cells compared to everolimus or NVP-BKM120.
PI3K/Akt/mTOR inhibitors effect on CXCL12-
induced MCL cell migration and invasion and 
tumor angiogenesis
To further validate GSEA results, we next 
explored the role of these PI3K/Akt/mTOR inhibitors 
in invasive and angiogenic processes in MCL. As tumor 
invasiveness couples with the migratory ability of 
cells, we first investigated the effect of these drugs on 
actin polymerization and cell chemotaxis in response 
to CXCL12. As shown in Figure 4A, CXCL12 induced 
a notable increase in actin polymerization that was 
significantly decreased only after NVP-BEZ235 
incubation (*, P < 0.05). MCL cells were then assayed 
for chemotaxis toward CXCL12. Figure 4B shows that 
everolimus and NVP-BEZ235 significantly reduced the 
number of migrating MCL cells in the presence of the 
chemokine (59.80 ± 6.87 % of inhibition for everolimus, 
66.87 ± 4.78 % of inhibition for NVP-BEZ235; *, P 
< 0.05), whereas NVP-BKM120 had no significant 
effect. We then examined the effect of these drugs on 
MCL invasive properties with matrigel-coated invasion 
chambers that simulate extracellular matrix. In response 
to CXCL12, untreated MCL cells passed through matrigel, 
however, NVP-BEZ235 significantly reduced CXCL12-
induced invasion (*, P < 0.05) whereas NVP-BKM120 
and everolimus did not (Figure 4C).
Finally, we analyzed the effect of these drugs 
on tumor angiogenesis with HUVEC tube formation 
assay. Supernatants from MCL cells treated with NVP-
BEZ235 were significantly less angiogenic than those 
from untreated MCL cells (*, P < 0.05), although MCL 
cells exposed to everolimus or NVP-BKM120 showed a 
tendency but not a significant decrease in the angiogenic 
activity on HUVEC cells (Figure 5A). 
All these results show that NVP-BEZ235 exerts a 
significant reduction of migratory, invasive and angiogenic 
properties of MCL cells.
DISCUSSION
MCL is characterized by an unfavorable clinical 
evolution being one of the most aggressive B-cell 
lymphomas. Furthermore, current conventional therapies 
are not able to control the long term evolution of the 
disease and the tumors present frequent relapses. The 
constitutive activation of the PI3K/Akt/mTOR signaling 
pathway, which is involved in the regulation of essential 
cellular functions, is commonly observed in many tumors, 
including MCL, and is critical for tumor progression and 
resistance to antineoplastic drugs.[3;9]
Antitumor activity has been observed with mTOR 
inhibitors as monotherapy or in combination. However, 
only a portion of relapsed/refractory MCL patients respond 
to the rapamycin analogues and the response is generally 
not durable.[28-32] It has been reported that several 
signaling feedback loops might attenuate the effectiveness 
of these compounds,[17] so dual catalytic inhibition of 
PI3K/mTOR could be a good strategy to address PI3K/
Akt/mTOR resistance mechanisms. 
Here, we have compared the effect of everolimus, 
an mTORC1 inhibitor, NVP-BEZ235, a dual inhibitor of 
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Figure 3: NVP-BEZ235 disrupts IL4 and IL6 signaling. A, Primary MCL cells were exposed to 5 μM everolimus, 1 μM NVP-
BEZ235 and 1 μM NVP-BKM120 for 8 hours and mRNA levels of the selected genes were examined by qRT-PCR. Relative mRNA 
expression levels were referred to untreated controls. Bars represent the mean ± SEM of all the samples tested (n=10). B, MCL cells were 
simultaneously incubated with IL4 (20 ng/mL) or IL6 (40 ng/mL) and the corresponding drugs (5 μM everolimus, 1 μM NVP-BEZ235 or 
1 μM NVP-BKM120). Cell viability was determined at 48 hours by Annexin V labeling and represented relative to the respective untreated 
control, with or without IL4 (n=8) or IL6 (n=7). Mean ± SEM of the cases analyzed. C, Western blot analysis of phosphorylated and total 
levels of STAT3 and STAT6 was performed after 30 minutes of simultaneous exposure of IL4 or IL6 and the corresponding drugs. β-actin 
or α-tubulin was probed as a loading control. Two representative cases are shown (MCL nº.1 and nº.7). Ratio between phosphorylated and 
total protein levels was calculated with Image Gauge software (Fujifilm). *, P < 0.05; **, P < 0.01; ns, not significant.
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PI3K and mTOR (mTORC1 and mTORC2) and NVP-
BKM120, a pan-PI3K inhibitor, in primary MCL cells. 
We observed that NVP-BEZ235 was more powerful 
than everolimus or NVP-BKM120 in PI3K/Akt/mTOR 
signaling inhibition and in cytotoxicity induction in the 
presence of stromal cells. Accordingly, the ability of NVP-
BEZ235 to overcome microenvironment signals has been 
previously reported in MCL cell lines.[25] Our results 
confirmed for the first time this effect in primary MCL 
cells. Thus, the use of the PI3K/mTOR dual inhibitor 
would support the idea that targeting PI3K/Akt/mTOR 
at multiple levels might be more efficient at inducing 
apoptosis in the presence of microenvironment signals 
and to prevent the development of drug resistance. This is 
in agreement with a previous report of our group, where 
we showed that dual mTORC1 and Akt targeting with 
everolimus and an isoselective Akt inhibitor, respectively, 
exerted synergistic antitumor activity in MCL.[18] 
Based on the differences in drug-related cytotoxic 
effect, GEP approach revealed that NVP-BEZ235 
treatment was associated with the highest number of 
modulated genes compared to NVP-BKM120 and 
everolimus, being the MTORC1 inhibitor the drug that 
induced the lowest number of gene changes. Consistently, 
Figure 4: PI3K/Akt/mTOR inhibitors effect on 
CXCL12-induced MCL cell migration and invasion. 
A, Primary MCL cells were preincubated with 5 μM everolimus, 
1 μM NVP-BEZ235 or 1 μM NVP-BKM120 for 1 hour before 
CXCL12 (200 ng/mL) addition. Polymerized actin content was 
determined at the indicated time points after CXCL12 addition. 
Results are displayed relative to the samples (n=7) before 
chemokine stimulation (100 %). Bars represent the mean ± SEM. 
B, MCL samples (n=7) were assayed for chemotaxis toward 
CXCL12 after 1 hour of preincubation with the drugs. Relative 
number of migrating cells to the untreated control without 
CXCL12 is represented. Bars correspond to the mean ± SEM. 
C, Samples (n=7) were assayed for invasion toward CXCL12 
through matrigel invasion chambers. Invasion is represented as 
the ratio between invasive cells and input viable cells, relative 
to the untreated control. Bars correspond to the mean ± SEM. 
*, P < 0.05.
Figure 5: NVP-BEZ235 downregulates angiogenesis in 
MCL cells. A, Supernatants from MCL cells were harvested 
after 8 hours of incubation with drugs and added to HUVEC 
cells for 24h. The number of branch points was quantified as the 
mean of 5 randomly chosen fields from each well, as relative 
to the untreated control. Bars represent the mean ± SEM of 6 
MCL cases. Microscope images (x40 magnification) from a 
representative case are shown (MCL nº.7). *, P < 0.05.
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NVP-BEZ235-treated MCL samples downregulated well-
known pathways affected by PI3K/Akt/mTOR inhibitors.
[2] In addition, we observed inhibition of pathways 
involved in angiogenesis, cell invasion and inflammation 
processes. Importantly, NVP-BEZ235 treatment 
downregulated IL6 and IL4 cytokine signaling pathways 
confirming an essential contribution of STAT family to the 
PI3K/mTOR pathway[33] in MCL. 
Interactions between the neoplastic B cells and 
accessory cells in tissue microenvironments, such as the 
lymphatic tissues, are critical for disease progression 
and chemoresistance in various B-cell malignancies.
[34] In MCL, STAT3 activation has shown to be either 
constitutively through a cytokine autocrine loop of IL6 
and/or IL10 secretion or in response to B-cell receptor 
engagement.[35] Moreover, IL6–mediated STAT3 
activation has recently been found to compromise the 
therapeutic effect of chemotherapy in MCL.[36] In this 
context, we demonstrated that NVP-BEZ235 was able 
to decrease STAT3 signaling in the presence of IL6, in 
contrast to everolimus or NVP-BKM120. Besides, NVP-
BEZ235 also downregulated the gene expression levels 
of HCK, IRF1, SP110 and STAT1, all genes related to the 
IL6 signaling pathway. As human bone marrow stromal 
cells have been described to secrete IL6,[37;38] we 
hypothesize that NVP-BEZ235 increased cytotoxicity in 
HS-5 coculture could be related to its ability to interfere 
with cytokine signaling.
Growth-promoting activity of IL4 by means of 
STAT6 phosphorylation has also been described in B-cell 
lymphomas.[33;39-41] Interestingly, NVP-BEZ235 
effectively overcame the prosurvival effect of IL4 as well 
as completely inhibited IL4 signaling. In addition, TLR4 
levels were also found to be downregulated by NVP-
BEZ235 treatment. A previous report described that the 
activation of TLR4 signaling in MCL cells, one of the 
predominant TLRs in these cells, induced proliferation 
and secretion of cytokines like IL6 and VEGF.[42] 
Recently, a whole-exome sequencing study detected 
recurrent activating mutations in TLR2 that increased the 
IL6 production among other chemokines.[43] Moreover, 
NVP-BEZ235 was found to inhibit multiple paracrine and 
autocrine survival growth factors in PI3K/Akt/mTOR-
addicted lymphomas.[19] Thus, our data support that 
NVP-BEZ235 treatment may interfere with cytokine 
signaling in MCL, which is crucial for keeping tumor 
thriving in its microenvironment. 
A key event in the development and progression of 
cancer is the potential of tumor cells to migrate and invade 
into surrounding tissues. In this context, we show for the 
first time that NVP-BEZ235 clearly reduced the migratory 
and invasive potential of MCL cells, as indicated in GEP 
data. Recently, ibrutinib[44] and sorafenib[45] have been 
described to inhibit migration of MCL cells, indicating 
the potential of the BCR-associated kinase inhibitors 
in modulating the homing of MCL cells into lymphoid 
tissues. Besides migratory and invasive processes, 
angiogenesis appears to be of particular importance in the 
physiopathology of lymphomas, as disease progression 
was found to correlate with increased angiogenic activity.
[46] In this sense, involvement of PI3K/Akt/mTOR 
pathway in cell invasion and angiogenesis has been 
proposed in follicular lymphoma.[47] Here, we provide 
the first evidence of NVP-BEZ235 ability to interfere with 
the angiogenic process. This effect could be related to the 
observed downregulation of STAT3 signaling, as it was 
demonstrated to participate in angiogenic responses in 
vivo.[48] 
MCL is one of the most difficult types of lymphoma 
to treat, which is due in part to its frequent relapses and 
progressive resistance to treatment suggesting that the 
microenvironment may sustain residual tumor cells 
resistant to chemotherapy.[1] Our findings suggest the use 
of NVP-BEZ235 as a therapeutic strategy to interfere with 
malignant cell/microenvironment interactions, thanks to its 
involvement in essential processes such as angiogenesis, 
migration, invasiveness and cytokine signaling. We 
propose that targeting the PI3K/Akt/mTOR pathway at 
multiple levels may therefore provide a more effective 
antitumor activity than the current strategies using mTOR 
inhibitors in MCL.
METHODS
Culture of primary and stromal cells
Primary cells from 11 patients diagnosed of MCL 
were obtained. The ethical approvals for this project 
including the informed consent of the patients were 
granted following the guidelines of the Hospital Clínic 
Ethics Committee and The Code of Ethics of the World 
Medical Association (Declaration of Helsinki). The 
characteristics of these patients are listed in Table 1. The 
DNA copy number alterations and mutational profile 
of these samples were previously characterized using 
Affymetrix 6.0 SNP arrays and whole-exome sequencing.
[43] Primary cryopreserved MCL cells were cultured as 
previously described.[18] When indicated, MCL cells were 
cocultured with the human bone marrow-derived stromal 
cell line HS-5 (ATCC) in 96-well plates as described.[10]
Treatments and flow cytometry analysis of 
apoptosis
Primary MCL cells were incubated as indicated 
with 5 µM everolimus, 1 µM NVP-BEZ235 or 1 µM 
NVP-BKM120 (all drugs kindly provided by Novartis). 
When indicated, cells were simultaneously incubated with 
interleukin 4 (IL4; 20 ng/mL) or interleukin 6 (IL6; 40 
ng/mL) and the drugs. Cell viability was quantified by 
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flow cytometry analysis after double labeling of cells for 
phosphatidylserine exposure with Annexin V-fluorescein 
isothiocyanate (FITC), and for nuclear membrane 
permeabilization with propidium iodide (PI; eBioscience). 
Annexin V-FITC and PI negative population was 
considered as viable cells. Labeled cells were acquired on 
an Attune cytometer (Life Technologies). 
Western blot analysis
Whole protein extraction and Western blot analysis 
were done as previously described.[18] Membranes were 
probed with the following primary antibodies from Cell 
Signaling Technology (Danvers): phospho-Akt (Ser473), 
phospho-ribosomal protein S6 (RPS6; Ser235/236), 
phospho-4EBP1 (Thr37/46), phospho-eIF4E (Ser209), 
phospho-STAT3 (Tyr705, clone D3A7), phospho-STAT6 
(Tyr641), Akt, RPS6, 4EBP1, eIF4E, STAT3 (clone 
79D7) and STAT6 (clone D3H4). Horseradish peroxidase-
labeled anti-mouse IgG (Sigma) and anti-rabbit IgG (Cell 
Signaling Technology) were used as secondary antibodies. 
Ratio between phosphorylated and total protein levels was 
calculated and relative protein quantification in treated 
versus control extracts was conducted with Image Gauge 
software (Fujifilm). Equal protein loading was confirmed 
by re-probing membranes with anti-β-actin or anti-α-
tubulin antibodies (Sigma). 
Gene expression profiling (GEP) 
Total RNA was isolated from primary MCL cells, 
previously exposed to 5 µM everolimus, 1 µM NVP-
BEZ235 or 1 µM NVP-BKM120 for 8 hours, using 
the TRIzol reagent (Life Technologies) according to 
manufacturer’s instructions. RNA integrity was examined 
with the Agilent 2100 Bioanalyzer (Agilent Technologies) 
and 150 ng of high quality RNA were used to generate 
biotin-labeled cRNA. After cRNA fragmentation, 
samples were hybridized on the HT HG-U219 GeneChip 
perfect-match-only array plate (Affymetrix) following 
standardized protocols. Scanning was processed in 
the Gene Titan instrument (Affymetrix) and analyzed 
with GeneChip Command Console Software (AGCC) 
(Affymetrix). Raw data were normalized using the Robust 
Multichip Analysis (RMA) algorithm implemented in the 
Expression Console Software v1.1 (Affymetrix). Raw data 
have been deposited in the Gene Expression Omnibus 
Database (accession number GSE53309).
Unsupervised hierarchical clustering of the 10000 
high-standard deviation genes was performed using 
Pearson’s correlation coefficient and average linkage, 
as the similarity measure and clustering algorithm 
respectively, within TM4-MultiExperiment Viewer 
platform. Genes modulated by a specific treatment were 
displayed with Cluster (version 2.11) and TreeView 
(version 1.6) softwares (Eisen Laboratory). The scaled 
expression value is plotted in red-blue color scale with red 
indicating high gene expression and blue indicating low 
gene expression. 
Gene set enrichment analysis (GSEA)
Significant gene signatures differentially regulated 
by each drug versus untreated cells were identified with 
GSEA version 2.0 (Broad Institute at MIT; http://www.
broadinstitute.org/gsea/) using the C2 (curated gene sets) 
collection from the Molecular Signature Database v2.5. 
A two-class analysis with 1000 permutations of gene 
sets and a weighted metric was used. Gene sets with a 
false discovery rate (FDR) below 0.05 were considered 
significant.
mRNA quantification by real-time PCR
Total RNA was extracted using TRIzol method 
(Life technologies) as above. In order to eliminate any 
traces of DNA, RNA was incubated with the DNA-free 
kit (Life Technologies). DNA-free RNA (0.5-1 μg) was 
retrotranscribed to cDNA using the High Capacity cDNA 
Reverse Transcription kit (Life Technologies). Then, 
samples were processed to Specific Target Amplification 
using the TaqMan PreAmp Master Mix and the TaqMan 
Gene Expression Assays (Life Technologies) for a 
multiplexed preamplification of the targets of interest 
(Supplementary Table A.1). Finally, samples were diluted 
1/5 in Tris-EDTA buffer and 48.48 Dynamic Array – 
Gene Expression IFC (Fluidigm Corporation) was run as 
recommended by the manufacturer, with the same TaqMan 
Gene Expression Assays as before. The relative expression 
of each gene was quantified by the comparative cycle 
threshold (Ct) method (ΔΔCt) using GUSB as endogenous 
control. mRNA expression levels are given in arbitrary 
units, taking as a reference the untreated control sample.
Chemotaxis and actin polymerization assays
CXCL12-induced chemotaxis and actin 
polymerization assays were performed as previously 
described.[10] Migration is represented as the relative 
number of migrating cells, taking as a reference the 
untreated control without CXCL12. As for actin 
polymerization assays, results are plotted relative to the 
mean fluorescence of the sample before the addition of 
CXCL12. 
Cell invasion assay
Primary MCL cells were serum-starved for 1.5 
hours in FBS-free RPMI 1640 (107 cells/mL). Next, cells 
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were diluted (5x106 cells/mL with 0.5 % BSA in RPMI 
1640), incubated with the corresponding drugs for 1 hour 
and afterwards, 100 µL were added to the top chambers of 
rehydrated BioCoat Matrigel Invasion Chambers (Becton 
Dickinson). Chambers had been previously transferred to 
wells containing 600 μL of 0.5 % BSA in RPMI 1640 with 
200 ng/mL of CXCL12. Input cell count was obtained 
from adding 100 μL of cell suspension to wells containing 
600 μL of 0.5 % BSA in RPMI 1640. After 24 hours of 
incubation, 100 μL were collected in triplicate from each 
lower chamber and input well, viable cells gated in a 
FSC/SSC plot and counted on an Attune cytometer under 
constant flow rate. Invasion is represented as the ratio 
between invasive cells and input viable cells, relative to 
the untreated control.
HUVEC tube formation assay
HUVEC cells, kindly provided by Dr MC Cid 
(IDIBAPS), were cultured in RPMI 1640 supplemented 
with 20 % defined bovine calf serum (Thermo Fisher 
Scientific), 0.2 mg/mL endothelial cell growth supplement 
(Becton Dickinson), 5 units/mL sodium heparin (EMD 
Millipore), 2 mM glutamine, 100 units/mL penicillin-
streptomycin, 50 μg/mL gentamycin (Life Technologies) 
and 2.5 μg/mL fungizone (Sigma). Supernatant from 
primary MCL cells (2x106 cells/mL) was collected after 
8 hours of incubation with drugs. Twenty-four-well plates 
were coated with 300 μL of Matrigel (Becton Dickinson) 
and allowed to polymerize for 30 minutes at 37ºC. 
Subsequently, 500 μL of the supernatant of interest and 
500 μL of HUVEC cells (0.8x105 cells/mL) in its medium 
were added into each culture well. After 24 hours of 
incubation, the number of branch points was quantified 
as the mean of 5 randomly chosen fields from each well. 
Images were taken at x40 magnification in a DM IL LED 
microscope coupled to a DFC295 camera with Leica 
Application Suite v 3.7 software (Leica). 
Statistical analysis
Nonparametric Wilcoxon signed rank test was used 
to compare the mean of a set of samples to a theoretical 
value. Comparison between two groups of samples 
was evaluated by non-parametric Wilcoxon paired 
t-test. Statistical analysis was conducted with the use of 
GraphPad Prism 4.0 software (GraphPad Software).
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